8-K: Amarin Receives Nasdaq Extension for Minimum Bid Price Compliance, Shares to Transfer to Capital Market

Amarin Corporation has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, resulting in a transfer of its listing to the Nasdaq Capital Market.

Summary

• Amarin Corporation received a notice from Nasdaq granting a 180-day extension, until May 19, 2025, to meet the minimum bid price requirement of $1.00 per share.
• The company's American Depositary Shares (ADS) will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective November 26, 2024.
• The ADS will continue to trade under the symbol AMRN during this period.
• To regain compliance, the closing bid price of Amarin's ADS must be at least $1.00 for a minimum of 10 consecutive business days before May 19, 2025.
• Amarin is considering options to resolve the deficiency, including a potential reverse stock split.
• There is no guarantee that Amarin will regain compliance or avoid delisting from Nasdaq.

Sentiment

Score: 3

Explanation: The document indicates a negative development with the transfer to the Nasdaq Capital Market and the risk of delisting, despite the extension. The company is facing challenges and uncertainty.

Positives

• Amarin has been granted additional time to regain compliance with Nasdaq's minimum bid price requirement.
• The company's shares will continue to trade on Nasdaq under the same symbol, AMRN, during the extension period.

Negatives

• Amarin's shares are being transferred to the Nasdaq Capital Market, which is generally associated with smaller companies.
• There is no guarantee that Amarin will regain compliance with the minimum bid price requirement.
• The company faces the risk of delisting from Nasdaq if it fails to meet the requirements by May 19, 2025.

Risks

• Amarin faces the risk of delisting from Nasdaq if it cannot maintain a share price of at least $1.00 for 10 consecutive business days before May 19, 2025.
• The transfer to the Nasdaq Capital Market could negatively impact investor perception and potentially the share price.
• The company may need to implement a reverse stock split, which could further impact the share price.

Future Outlook

Amarin intends to actively monitor its share price and consider available options, including a reverse stock split, to regain compliance with Nasdaq's minimum bid price requirement, but there is no assurance of success.

Management Comments

• Amarin intends to continue actively monitoring the bid price for its ADS between now and May 19, 2025.
• Amarin will continue considering available options to resolve the deficiency and regain compliance with the Bid Price Requirement.

Industry Context

This announcement reflects the challenges faced by some pharmaceutical companies in maintaining share price compliance, particularly those with volatile stock performance or facing market pressures.

Comparison to Industry Standards

• Many companies in the biotech and pharmaceutical sector face similar challenges with maintaining minimum share price requirements on major exchanges.
• Companies like Omeros Corporation and Cassava Sciences have also faced similar delisting risks and have had to implement reverse stock splits or other measures to regain compliance.
• The transfer to the Nasdaq Capital Market is a common step for companies that fail to meet the requirements of the Global Market, indicating a need for improved financial performance or market perception.

Stakeholder Impact

• Shareholders face the risk of further share price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial challenges.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Amarin will actively monitor its share price.
• Amarin will consider options to regain compliance, including a potential reverse stock split.
• Amarin must achieve a closing bid price of at least $1.00 for 10 consecutive business days before May 19, 2025, to avoid delisting.

Key Dates

Keywords

Nasdaq, minimum bid price, delisting, compliance, reverse stock split, AMRN, Nasdaq Capital Market, extension